GlassScriptPhysician profile
Tabatha Ann Garza
NPI 1710466826
$1,800.68
in general payments reported to CMS, 2019-2025
12 companies · $980 in 2025
The $980 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $61.44 · 2023: $370 · 2024: $389 · 2025: $980.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,739.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $346.48 | 2022-2025 | Ams 700, Watchman Flx |
| Kyowa Kirin, INC. | $241.10 | 2024-2025 | |
| Abbott Laboratories | $220.38 | 2023 | Freestyle Libre 3, Ensite Precision |
| Janssen Pharmaceuticals, INC | $137.86 | 2024 | Spravato |
| Abiomed | $137.16 | 2025 | |
| Acadia Pharmaceuticals INC | $122.17 | 2025 | Daybue |
| Teva Pharmaceuticals USA, INC. | $114.14 | 2025 | Austedo Xr |
| Amarin Pharma, INC. | $112.65 | 2025 | Vascepa |
| Edwards Lifesciences Corporation | $109.33 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| W. L. Gore & Associates, INC. | $91.98 | 2024 | Gore Viabahn Endoprosthesis With Heparin |
| Cvrx, INC. | $88.53 | 2025 | Barostim Neo System |
| Coloplast Corp | $78.90 | 2023-2024 | Altis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tabatha Garza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.